Forma Therapeutics Holdings Current Ratio 2019-2021 | FMTX

Forma Therapeutics Holdings current ratio from 2019 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Forma Therapeutics Holdings Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.56B $0.03B 17.94
2021-03-31 $0.57B $0.03B 20.10
2020-12-31 $0.65B $0.03B 20.65
2020-09-30 $0.42B $0.03B 13.55
2020-06-30 $0.46B $0.03B 18.34
2020-03-31 $0.18B $0.02B 8.07
2019-12-31 $0.18B $0.03B 7.13
2019-09-30 $0.00B 0.00
2019-06-30 $0.00B 0.00
2019-03-31 $0.00B 0.00
2018-12-31 $0.26B $0.23B 1.09
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.111B $0.101B
Forma Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics with rare hematologic diseases and cancers. Forma Therapeutics Holdings Inc. is based in Watertown, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71